ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sitagliptin

Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.

Drug pageSitagliptin: every studyMany companies study it; this page follows only the 101 they lead. All 306 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 28, 2009101 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only780 open or runningphase 4since Jan 28, 2009Jul 2, 2004none ahead
Ono Pharmaceuticalits history only50 open or runningphase 3since Aug 11, 2006Aug 11, 2006none ahead
ADIUMits history only40 open or runningno phasesince Aug 10, 2026Aug 10, 2026none ahead
Novo Nordiskits history only40 open or runningphase 4since Jan 24, 2012Jun 18, 2008none ahead
Bio-innovaits history only22 open or runningphase 1since Dec 15, 2023Dec 15, 2023none ahead
Novartis20 open or runningphase 4since Sep 13, 2012Jun 12, 2012none ahead
Profil Institut für Stoffwechselforschungits history only20 open or runningphase 2since Aug 28, 2013Aug 28, 2013none ahead
Chong Kun Dang Pharmaceuticalits history only10 open or runningphase 1since Jun 30, 2016Jun 30, 2016none ahead
Dong Wha Pharmaceuticalits history only10 open or runningphase 1since May 4, 2022May 4, 2022none ahead
Getz Pharmaits history only10 open or runningphase 4since Nov 29, 2021Nov 29, 2021none ahead

Also a collaborator on its studies: Parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2012First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT01619332 · 220 enrolled · United States
  2. Sep 13, 2012Phase 4 study in Diabetes Mellitus, Type 2NCT01686932 · 51 enrolled · Germany
  3. Jul 21, 2022Named sitagliptinINNProposed as its International Nonproprietary Name in WHO's List 127

TargetBeta

DPP4 →read by rule
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
LinagliptinruleBoehringer Ingelheimphase 496
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

All 2 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01686932Diabetes Mellitus, Type 2 · Germany4CompletedSep 201451
NCT01619332Diabetes Mellitus, Type 2 · United States2CompletedSep 2013220

How it is read

Names in the registry

  • “Sitagliptin”, 33 entries
  • “sitagliptin phosphate”, 18 entries
  • “sitagliptin”, 15 entries
  • “Sitagliptin phosphate”, 10 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: MK0431.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.